Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors

Optimal isodose line fitting to the planning target volume

Yohei Oku, Atsuya Takeda, Naoko Sanuki, Yasunobu Sudo, Yoshikazu Oooka, Yousuke Aoki, Yoshiaki Shimouchi, Ryohei Nishina, Kazuhiro Nomura, Takahisa Eriguchi, Etsuo Kunieda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To assess optimal relative prescribed dose values in stereotactic ablative body radiation therapy (SABR) using dynamic conformal multiple arc therapy (DCMAT) for liver tumors. Methods and Materials: We generated SABR plans for 8 typical liver tumors that received SABR with 50 Gy in 5 fractions. The prescribed dose had previously been defined as 80% of the maximal dose ("80% isodose plan"). Alternatively, 20%-90% isodose plans were created to compare dosimetric factors. Results: The mean liver volume values (%) that received >. 20 Gy (V20) and the mean liver dose were both the lowest with a 70% isodose plan and were the second lowest with a 60% isodose plan. The V20 dose was 5.19% lower (11.14%) with a 70% isodose plan and 4.51% lower (11.22%) with a 60% isodose plan compared with the value with an 80% isodose plan (11.75%). Mean planning target volume (PTV) dose increased as the % isodose decreased. The mean PTV dose was 10% higher (62.4 Gy) with a 70% isodose plan and 21% higher (68.9 Gy) with a 60% isodose plan compared with the value with an 80% isodose plan (56.8 Gy). Conclusions: During SABR treatment planning using DCMAT for liver tumors, target doses increased as the percentage isodose value decreased, which could result in better outcomes. In contrast, a 70% isodose plan had the lowest normal liver dose and a 60% isodose plan had the second lowest. An optimal percentage isodose level might be adjusted depending on tumor radiation sensitivity and liver function reserve. Further investigation is warranted to determine whether these dosimetric advantages result in improved outcomes.

Original languageEnglish
JournalPractical Radiation Oncology
Volume4
Issue number1
DOIs
Publication statusPublished - 2014 Jan
Externally publishedYes

Fingerprint

Radiotherapy
Liver
Neoplasms
Therapeutics
Radiation Tolerance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors : Optimal isodose line fitting to the planning target volume. / Oku, Yohei; Takeda, Atsuya; Sanuki, Naoko; Sudo, Yasunobu; Oooka, Yoshikazu; Aoki, Yousuke; Shimouchi, Yoshiaki; Nishina, Ryohei; Nomura, Kazuhiro; Eriguchi, Takahisa; Kunieda, Etsuo.

In: Practical Radiation Oncology, Vol. 4, No. 1, 01.2014.

Research output: Contribution to journalArticle

Oku, Yohei ; Takeda, Atsuya ; Sanuki, Naoko ; Sudo, Yasunobu ; Oooka, Yoshikazu ; Aoki, Yousuke ; Shimouchi, Yoshiaki ; Nishina, Ryohei ; Nomura, Kazuhiro ; Eriguchi, Takahisa ; Kunieda, Etsuo. / Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors : Optimal isodose line fitting to the planning target volume. In: Practical Radiation Oncology. 2014 ; Vol. 4, No. 1.
@article{73830934d6d34ebb904011877aa77d80,
title = "Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors: Optimal isodose line fitting to the planning target volume",
abstract = "Purpose: To assess optimal relative prescribed dose values in stereotactic ablative body radiation therapy (SABR) using dynamic conformal multiple arc therapy (DCMAT) for liver tumors. Methods and Materials: We generated SABR plans for 8 typical liver tumors that received SABR with 50 Gy in 5 fractions. The prescribed dose had previously been defined as 80{\%} of the maximal dose ({"}80{\%} isodose plan{"}). Alternatively, 20{\%}-90{\%} isodose plans were created to compare dosimetric factors. Results: The mean liver volume values ({\%}) that received >. 20 Gy (V20) and the mean liver dose were both the lowest with a 70{\%} isodose plan and were the second lowest with a 60{\%} isodose plan. The V20 dose was 5.19{\%} lower (11.14{\%}) with a 70{\%} isodose plan and 4.51{\%} lower (11.22{\%}) with a 60{\%} isodose plan compared with the value with an 80{\%} isodose plan (11.75{\%}). Mean planning target volume (PTV) dose increased as the {\%} isodose decreased. The mean PTV dose was 10{\%} higher (62.4 Gy) with a 70{\%} isodose plan and 21{\%} higher (68.9 Gy) with a 60{\%} isodose plan compared with the value with an 80{\%} isodose plan (56.8 Gy). Conclusions: During SABR treatment planning using DCMAT for liver tumors, target doses increased as the percentage isodose value decreased, which could result in better outcomes. In contrast, a 70{\%} isodose plan had the lowest normal liver dose and a 60{\%} isodose plan had the second lowest. An optimal percentage isodose level might be adjusted depending on tumor radiation sensitivity and liver function reserve. Further investigation is warranted to determine whether these dosimetric advantages result in improved outcomes.",
author = "Yohei Oku and Atsuya Takeda and Naoko Sanuki and Yasunobu Sudo and Yoshikazu Oooka and Yousuke Aoki and Yoshiaki Shimouchi and Ryohei Nishina and Kazuhiro Nomura and Takahisa Eriguchi and Etsuo Kunieda",
year = "2014",
month = "1",
doi = "10.1016/j.prro.2013.04.001",
language = "English",
volume = "4",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors

T2 - Optimal isodose line fitting to the planning target volume

AU - Oku, Yohei

AU - Takeda, Atsuya

AU - Sanuki, Naoko

AU - Sudo, Yasunobu

AU - Oooka, Yoshikazu

AU - Aoki, Yousuke

AU - Shimouchi, Yoshiaki

AU - Nishina, Ryohei

AU - Nomura, Kazuhiro

AU - Eriguchi, Takahisa

AU - Kunieda, Etsuo

PY - 2014/1

Y1 - 2014/1

N2 - Purpose: To assess optimal relative prescribed dose values in stereotactic ablative body radiation therapy (SABR) using dynamic conformal multiple arc therapy (DCMAT) for liver tumors. Methods and Materials: We generated SABR plans for 8 typical liver tumors that received SABR with 50 Gy in 5 fractions. The prescribed dose had previously been defined as 80% of the maximal dose ("80% isodose plan"). Alternatively, 20%-90% isodose plans were created to compare dosimetric factors. Results: The mean liver volume values (%) that received >. 20 Gy (V20) and the mean liver dose were both the lowest with a 70% isodose plan and were the second lowest with a 60% isodose plan. The V20 dose was 5.19% lower (11.14%) with a 70% isodose plan and 4.51% lower (11.22%) with a 60% isodose plan compared with the value with an 80% isodose plan (11.75%). Mean planning target volume (PTV) dose increased as the % isodose decreased. The mean PTV dose was 10% higher (62.4 Gy) with a 70% isodose plan and 21% higher (68.9 Gy) with a 60% isodose plan compared with the value with an 80% isodose plan (56.8 Gy). Conclusions: During SABR treatment planning using DCMAT for liver tumors, target doses increased as the percentage isodose value decreased, which could result in better outcomes. In contrast, a 70% isodose plan had the lowest normal liver dose and a 60% isodose plan had the second lowest. An optimal percentage isodose level might be adjusted depending on tumor radiation sensitivity and liver function reserve. Further investigation is warranted to determine whether these dosimetric advantages result in improved outcomes.

AB - Purpose: To assess optimal relative prescribed dose values in stereotactic ablative body radiation therapy (SABR) using dynamic conformal multiple arc therapy (DCMAT) for liver tumors. Methods and Materials: We generated SABR plans for 8 typical liver tumors that received SABR with 50 Gy in 5 fractions. The prescribed dose had previously been defined as 80% of the maximal dose ("80% isodose plan"). Alternatively, 20%-90% isodose plans were created to compare dosimetric factors. Results: The mean liver volume values (%) that received >. 20 Gy (V20) and the mean liver dose were both the lowest with a 70% isodose plan and were the second lowest with a 60% isodose plan. The V20 dose was 5.19% lower (11.14%) with a 70% isodose plan and 4.51% lower (11.22%) with a 60% isodose plan compared with the value with an 80% isodose plan (11.75%). Mean planning target volume (PTV) dose increased as the % isodose decreased. The mean PTV dose was 10% higher (62.4 Gy) with a 70% isodose plan and 21% higher (68.9 Gy) with a 60% isodose plan compared with the value with an 80% isodose plan (56.8 Gy). Conclusions: During SABR treatment planning using DCMAT for liver tumors, target doses increased as the percentage isodose value decreased, which could result in better outcomes. In contrast, a 70% isodose plan had the lowest normal liver dose and a 60% isodose plan had the second lowest. An optimal percentage isodose level might be adjusted depending on tumor radiation sensitivity and liver function reserve. Further investigation is warranted to determine whether these dosimetric advantages result in improved outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84890884418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890884418&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2013.04.001

DO - 10.1016/j.prro.2013.04.001

M3 - Article

VL - 4

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 1

ER -